GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » Retained Earnings

Shanghai Medicilon (SHSE:688202) Retained Earnings : ¥653 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Medicilon Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Shanghai Medicilon's retained earnings for the quarter that ended in Mar. 2024 was ¥653 Mil.

Shanghai Medicilon's quarterly retained earnings declined from Sep. 2023 (¥832 Mil) to Dec. 2023 (¥690 Mil) and declined from Dec. 2023 (¥690 Mil) to Mar. 2024 (¥653 Mil).

Shanghai Medicilon's annual retained earnings increased from Dec. 2021 (¥517 Mil) to Dec. 2022 (¥758 Mil) but then declined from Dec. 2022 (¥758 Mil) to Dec. 2023 (¥690 Mil).


Shanghai Medicilon Retained Earnings Historical Data

The historical data trend for Shanghai Medicilon's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Medicilon Retained Earnings Chart

Shanghai Medicilon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160.43 283.78 516.82 757.53 690.39

Shanghai Medicilon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 859.10 883.20 831.97 690.39 652.83

Shanghai Medicilon Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Shanghai Medicilon  (SHSE:688202) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Shanghai Medicilon (SHSE:688202) Business Description

Traded in Other Exchanges
N/A
Address
Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.

Shanghai Medicilon (SHSE:688202) Headlines

No Headlines